Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Phase II Study Starts In Three European Countries
Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark.
